Policy Outlook: Understanding the Effects of the U.S. Inflation Reduction Act

With the passage of the U.S. Inflation Reduction Act in August, biopharma companies must consider how this impacts their portfolio. Will companies adjust their R&D investments? Will investors become more hesitant?  This session will cover how to navigate the new law as executives consider the strategic, business development, and legal implications.